Tilray Brands Delivers Record Q2 Fiscal 2024 Net Revenue
- Record net revenue of $194 million, a 34% increase over the prior year period
- 31% growth in Canadian cannabis net revenue and 55% growth in international cannabis net revenue
- 117% increase in beverage alcohol net revenue
- On track to achieve $30-$35 million in annual savings related to the integration of HEXO acquisition
- Strong financial liquidity position of ~$261 million
- Net loss decreased to $46 million
- Operating cash flow was $(30) million in the second quarter
Insights
The reported net revenue increase of 34% to $194 million is a significant indicator of Tilray Brands' growth trajectory, especially when dissected alongside the gross profit increase of 11% to $47 million. A deeper dive into the financials reveals a mixed picture: while revenue is up, the gross margin has decreased from the prior year, indicating potential increases in cost of goods sold or changes in product mix. The 117% increase in beverage alcohol net revenue is particularly noteworthy as it suggests successful market penetration and may predict future revenue streams. However, the reduction in gross margin in this segment from 47% to 34% raises questions about the cost structure and scalability of this growth.
The cash position of approximately $261 million, with a notable reduction in convertible debt, reflects a stronger balance sheet and improved financial flexibility. However, the operating cash flow turning negative to $(30) million, compared to $29 million in the prior year, warrants attention as it could signal underlying issues with cash management or operational efficiency.
Investors should closely monitor the company's ability to maintain revenue growth while managing costs to improve profitability. Additionally, the integration of HEXO acquisition and its expected $30-$35 million in annual savings could be crucial for long-term financial health and competitive positioning within the industry.
Tilray Brands' strategic positioning as a leader in both the Canadian cannabis market and the craft beverage-alcohol industry in the U.S. demonstrates a diversified approach to growth. The company's market share in Canada and its ascent to the 5th largest craft beer brewer in the U.S. are indicative of successful brand and product development strategies. The acquisition of brands from Anheuser-Busch has evidently contributed to significant revenue growth in the beverage sector, but it is essential to assess whether this growth is sustainable and can continue without sacrificing profit margins.
Expansion into the European medical cannabis market and growth in international cannabis net revenue by 55% suggests effective international market penetration, which could be a critical driver for future growth. The potential for entering the U.S. cannabis market upon federal legalization could present a significant opportunity, but it remains speculative and contingent on changes in federal law.
Investors should consider the company's ability to leverage its current market positions to further penetrate and expand into new markets, particularly focusing on the operational and regulatory challenges that may arise in these endeavors.
The mention of Tilray Brands' strategy in anticipation of potential U.S. federal cannabis legalization highlights the importance of regulatory developments on business operations. The company's current non-participation in U.S. cannabis operations due to federal restrictions underscores the regulatory barriers that exist in the industry. The strategic investment in MedMen is an example of how companies navigate these regulations while preparing for potential market entry.
Understanding the legal landscape and its implications is crucial for stakeholders, as shifts in policy could dramatically alter the competitive dynamics and profitability of cannabis-related businesses. The ability to quickly adapt to regulatory changes is a competitive advantage that can lead to first-mover benefits in newly legalized markets.
Stakeholders should remain informed on legislative developments and assess the company's readiness and strategic positioning to capitalize on regulatory changes, keeping in mind that such changes can also introduce new compliance costs and competitive pressures.
Record Q2 Net Revenue of
Global Cannabis Leader with #1 Market Share in Canada and
5th Largest Craft Beer Brewer in the U.S.1, Positioned to Become Top 12 Beverage-Alcohol Company with
On Track to Achieve
Reiterates Financial Guidance for Fiscal Year 2024
Conference Call to be Held at 8:30 a.m. ET Today
NEW YORK and LEAMINGTON, Ontario, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for its second quarter of its fiscal year 2024 ended November 30, 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Financial Highlights – 2024 Fiscal Second Quarter
- Record net revenue of
$194 million increased34% in the second quarter compared to$144 million in the prior year quarter.
- Gross profit increased
11% to$47 million , while adjusted gross profit increased18% to$52 million in the second quarter. Gross margin was24% and adjusted gross margin was27% . - Cannabis net revenue increased
35% to$67 million in the second quarter compared to$50 million in the prior year quarter.- Cannabis gross margin was
31% in the second quarter compared to43% in the prior year quarter. Adjusted cannabis gross margin was35% compared to43% in the prior year quarter.
- Cannabis gross margin was
- Beverage alcohol net revenue increased
117% to$47 million in the second quarter from$21 million in the prior year quarter.- Beverage alcohol gross margin was
34% in the second quarter compared to47% in the prior year quarter and adjusted gross beverage alcohol margin was38% in the second quarter compared to52% in the prior quarter. Excluding the newly acquired brands, adjusted gross margin would have been55% in the current quarter. - Beverage alcohol gross profit increased to
$16 million in the second quarter from$10 million in the prior year quarter. Adjusted beverage alcohol gross profit increased to$18 million from$11 million in the prior year quarter.
- Beverage alcohol gross margin was
- Distribution net revenue increased
12% to$67 million in the second quarter compared to$60 million in the prior year quarter.- Distribution gross margin was
11% in the second quarter compared to13% in the prior year quarter, reflecting a change in product mix.
- Distribution gross margin was
- Net loss decreased to
$46 million in the second quarter compared to net loss of$62 million in the prior year quarter. Net loss per share narrowed to ($0.07) compared to ($0.11) in the prior year quarter. - Adjusted net loss of
$2.7 million in the second quarter. Adjusted loss per share of$(0.00) . - Adjusted EBITDA was
$10.1 million in the second quarter compared to$11.0 million in the prior year quarter. The difference was primarily related to the HEXO advisory fee revenue in the prior year quarter along with timing differences in recognizing synergies from operating results after completing acquisitions. - Achieved
$22 million in annualized run-rate savings (and$14 million in actual cash cost savings) as part of the$30 million synergy plan related to the HEXO acquisition. - Strong financial liquidity position of ~
$261 million , consisting of$143 million in cash, including restricted cash of$1.5 million and$116 million in marketable securities. - Reduced outstanding convertible debt by
$127 million compared to the first quarter and a further$18 million subsequent to the end of our second quarter. - Operating cash flow of
$(30) million in the second quarter compared to$29 million in the prior year quarter. The increased cash use was primarily related to the settlement of pre-acquisition liabilities and exit costs assumed in connection with the HEXO acquisition. In addition, the prior year period included the cash collection of$18 million related to the purchase price derivative related to our acquisition of the HEXO convertible notes, which did not recur in the current year.
Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer, stated, “Tilray Brands is a major force at the forefront of innovation, disrupting the global CPG industry across medical and adult-use cannabis, wellness foods and snacks, and craft beverages. Our Q2 financial results demonstrate the strength of our brands, our global team, and our diversified growth strategy. We grew revenue, enhanced our capital structure, and realized operating synergies while strengthening Tilray Brands’ position as the #1 cannabis operation and brand portfolio in Canada by sales volume and market share, the European market leader in medical cannabis, and the leader in branded hemp products. We have also emerged as a disruptor in the craft beverage-alcohol industry by assembling a portfolio of highly sought-after brands that are dominating key regions across the U.S. in the Northeast, the Pacific Northwest, and the Southeast. Tilray is now uniquely positioned to become a top 12 beer and alcohol beverage company in the U.S.”
Mr. Simon continued, “Having already demonstrated success in solidifying our brands through products that connect with consumers, we will continue to deploy successful playbooks for growth across our brand portfolio and key regions in the U.S., Canada, and Europe. With each achievement and the support we have garnered from retailers, distributors, and consumers, I am confident that Tilray Brands will continue to lead and advance the global cannabis industry, disrupt the craft beer market, and fuel consumer needs in wellness foods.”
Operating Highlights
Strengthened Operations and Financial Position
- Significantly reduced convertible debt by
$127 million of principal of outstanding notes and an additional$18 million subsequent to the quarter ended November 30, 2023, for a total debt reduction of$145 million . The Company intends to continue to opportunistically repurchase additional notes to demonstrate and reinforce its commitment to optimizing its capital structure and enhancing financial flexibility. - Achieved
$22 million in operational synergies and identified an additional$5 million cost savings expected to be realized during the back half of the fiscal year. In aggregate, it is expected that total cost savings related to the HEXO and Truss integration will amount to$30 -$35 million in this fiscal year.
Leading Global Cannabis Operations, Brands, and Market Share
- Tilray continues to lead the Canadian cannabis market in revenue, sales volume, and market share with a
12.5% position during the second quarter. The Company led with #1 share in Cannabis Flower, Oils, Concentrates and THC Beverage product categories. - The HEXO Corp. and Truss Beverage acquisitions together significantly bolstered Tilray’s dominant cannabis position and strengthened low-cost operations and complementary distribution across all Canadian geographies.
- Tilray is focused on growing its leading market share in medical cannabis across Europe and other international markets. This will be accomplished by capitalizing on its unrivaled cultivation and distribution operations and the leadership team’s depth of commercial and regulatory expertise. During the second quarter, the increase in international cannabis revenue was largely driven by expansion into emerging international medical markets.
- In the U.S. today, Tilray does not participate in any cannabis operations and therefore, does not derive any revenue or cash from any cannabis operations in the U.S. The rescheduling of cannabis could open a path for Tilray to leverage its expertise in Canadian and European medical cannabis to distribute medical cannabis in the U.S. In the event of federal cannabis legalization in the U.S., we believe that Tilray is well-positioned to immediately leverage its strong U.S. leadership position and strategic strengths across operations, distribution, and brands to include THC-infused products. We further believe that our MedMen investment in the U.S. will position us to maximize commercial opportunities providing additional revenue opportunities in cannabis.
Growing Leadership Position in CPG and Beverage-Alcohol
- In September 2023, Tilray Brands expanded its beverage portfolio of Sweetwater Brewing Company, Alpine Brewing, Green Flash Brewing, Montauk Brewing, and Breckenridge Distillery by closing on its acquisition of eight beer and beverage brands from Anheuser-Busch (NYSE: BUD). The acquired brands are Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy (the “Craft Acquisition”). These premium craft brands possess strong consumer loyalty and further diversify Tilray’s U.S. beverage-alcohol segment, which more than doubled in Q2, and elevated Tilray to the 5th largest position in the U.S. craft beer market. Tilray Brands now seeks to become a top 12 U.S. beer and alcohol beverage company through a strategic three-pronged approach that consists of a regional brand growth, national brand expansion, and innovation strategy.
- Tilray’s wellness brand, Manitoba Harvest, expanded its brand leadership position in the U.S. and Canada with increased consumption in both the natural and conventional channels. For the remainder of the fiscal year, Manitoba Harvest will seek to expand the Happy Flower™ beverage brand with retail distribution into key markets, focusing on U.S. states with established CBD permissibility and sales momentum in future periods.
Fiscal Year 2024 Guidance
For its fiscal year ending May 31, 2024, the Company is reiterating its adjusted EBITDA target of
Management’s guidance for adjusted EBITDA is provided on a non-GAAP basis and excludes transaction expenses, restructuring charges, litigation costs, facility start-up and closure costs, , purchase price accounting step-up, changes in fair value of contingent consideration and other items carried at fair value, non-operating income (expenses), and other non-recurring items that may be incurred during the Company's fiscal year 2024, which the Company will continue to identify as it reports its future financial results. Management’s guidance for adjusted free cash flow is provided on a non-GAAP basis and excludes our growth capex, projected integration costs related to HEXO and the Craft Acquisition, and the cash income taxes related to Aphria Diamond.
The Company cannot reconcile its expected adjusted EBITDA to net income or adjusted free cash flow to operating cash flow under “Fiscal Year 2024 Guidance” without unreasonable effort because of certain items that impact net income and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time.
Tilray Brands Strategic Growth Actions – 2024 Fiscal Second Quarter
November 2023
- 10 Barrel Brewing Co. Launches Revitalized Hopburst IPA Collection
- Redecan Cannabis Launches New Holiday Style Redees
- Crafted for the People: SweetWater's New 'Half-A-Gummie' IPA Meets Consumer Demand for Fruity, Easy-Drinking Beers
- Tilray Brands Expands Cannabis Beverage Portfolio with New THC, CBG and CBD Drink Innovations by Top-Performing Canadian Brands
- Good Supply™ Cannabis Launches 'Get Blitzen’d' Holiday Campaign and New Limited-Edition Products Across Canada
- SweetWater Brewing Company Launches Special-Edition 420 IPA in Partnership With the Georgia Aquarium, One of the Top Aquariums in the World
October 2023
- Blue Point Brewing Announces Cask Ales Festival and New Beer Lineup
- Sweetwater Brewing Company Unveils Fall Craft Beer Lineup
- Celebrating Five Years of Growth: Tilray Brands Reflects on Industry Leadership in Canadian Cannabis and Looks Forward to its Future
- Good Supply, Tilray’s Best-Selling Cannabis Brand, Launches New Sustainability Campaign, ‘Green You Can Feel Good About’, and Debuts New Hemp Packaging
- Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment
- Montauk Releases Major Wave Chaser Double India Pale Ale
- Tilray Brands Closes Transaction Acquiring Eight Beer & Beverage Brands From Anheuser-Busch; Solidifies Leadership Position in U.S. Craft Beer Market
September 2023
- ‘Potently Canadian' Cannabis Brand, CANACA, Launches ‘Let ‘Er Rip’ Campaign
- Tilray’s Best-Selling Beers Make Landfall at Atlantis, Bahamas
- Montauk Brewing Expands Distribution Beyond the Northeast
- Tilray Expands Market Leading Cannabis Portfolio with Launch of New Redecan Products Across Canada
Live Audio Webcast
Tilray Brands will host a webcast to discuss these results today at 8:30 a.m. Eastern Time. Investors may join the live webcast available on the Investors section of the Company’s website at www.Tilray.com. A replay will be available and archived on the Company’s website.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY and TSX: TLRY) is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and well-being through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information on Tilray, visit Tilray Brands, Inc. and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn.
Cautionary Statement Concerning Forward-Looking Statements
Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become the world's leading cannabis-focused consumer branded company; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully achieve revenue growth, production and supply chain efficiencies, synergies and cost savings; the Company’s ability to generate
Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including Adjusted gross margin, Adjusted gross profit, Adjusted EBITDA, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, adjusted free cash flow, constant currency presentations of revenue and cash and marketable securities. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.
Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company's GAAP financial results.
The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company's consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.
Adjusted EBITDA is calculated as net income (loss) before income tax benefits, net; interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; facility start-up and closure costs; litigation costs; restructuring costs and transaction (income) costs. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Historically, we have included lease expenses for leases that were treated differently under IFRS 16 and ASC 842 in the calculation of adjusted EBITDA, aiming to align our definition with industry peers reporting under IFRS. The decision to include these lease expenses in the Company's definition of adjusted EBITDA was based on our efforts to maintain comparability with peers. However, as the Company has continued to diversify, particularly with strategic acquisitions such as the newly acquired beverage alcohol business portfolio, this comparison is no longer relevant, accordingly, we are no longer including this adjustment. Had the Company continued to include lease expenses that were treated differently under IFRS 16 and ASC 842, the impact to adjusted EBITDA would have been
Contacts:
Media:
Berrin Noorata
news@tilray.com
Investors:
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com
Consolidated Statements of Financial Position
| November 30, | May 31, | |||||
| (in thousands of US dollars) | 2023 | 2023 | ||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 143,373 | $ | 206,632 | ||
| Restricted cash | 1,576 | - | ||||
| Marketable securities | 116,418 | 241,897 | ||||
| Accounts receivable, net | 90,596 | 86,227 | ||||
| Inventory | 252,702 | 200,551 | ||||
| Prepaids and other current assets | 36,626 | 37,722 | ||||
| Assets held for sale | 736 | - | ||||
| Total current assets | 642,027 | 773,029 | ||||
| Capital assets | 615,087 | 429,667 | ||||
| Operating lease, right-of-use assets | 13,551 | 5,941 | ||||
| Intangible assets | 953,419 | 973,785 | ||||
| Goodwill | 2,009,714 | 2,008,843 | ||||
| Interest in equity investees | 4,638 | 4,576 | ||||
| Long-term investments | 8,034 | 7,795 | ||||
| Convertible notes receivable | 74,681 | 103,401 | ||||
| Other assets | 9,406 | 222 | ||||
| Total assets | $ | 4,330,557 | $ | 4,307,259 | ||
| Liabilities | ||||||
| Current liabilities | ||||||
| Bank indebtedness | $ | 20,181 | $ | 23,381 | ||
| Accounts payable and accrued liabilities | 216,898 | 190,682 | ||||
| Contingent consideration | 7,704 | 16,218 | ||||
| Warrant liability | 3,768 | 1,817 | ||||
| Current portion of lease liabilities | 5,043 | 2,423 | ||||
| Current portion of long-term debt | 12,993 | 24,080 | ||||
| Current portion of convertible debentures payable | 128,399 | 174,378 | ||||
| Total current liabilities | 394,986 | 432,979 | ||||
| Long - term liabilities | ||||||
| Contingent consideration | 13,000 | 10,889 | ||||
| Lease liabilities | 69,974 | 7,936 | ||||
| Long-term debt | 169,099 | 136,889 | ||||
| Convertible debentures payable | 123,691 | 221,044 | ||||
| Deferred tax liabilities | 166,454 | 167,364 | ||||
| Other liabilities | - | 215 | ||||
| Total liabilities | 937,204 | 977,316 | ||||
| Commitments and contingencies (refer to Note 19) | ||||||
| Stockholders' equity | ||||||
| Common stock ( | 73 | 66 | ||||
| Preferred shares ( | - | - | ||||
| Additional paid-in capital | 5,942,671 | 5,777,743 | ||||
| Accumulated other comprehensive loss | (38,367 | ) | (46,610 | ) | ||
| Accumulated Deficit | (2,536,040 | ) | (2,415,507 | ) | ||
| Total Tilray Brands, Inc. stockholders' equity | 3,368,337 | 3,315,692 | ||||
| Non-controlling interests | 25,016 | 14,251 | ||||
| Total stockholders' equity | 3,393,353 | 3,329,943 | ||||
| Total liabilities and stockholders' equity | $ | 4,330,557 | $ | 4,307,259 | ||
Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
| For the three months | For the six months | ||||||||||||||||||||||||||||||
| ended November 30, | Change | % Change | ended November 30, | Change | % Change | ||||||||||||||||||||||||||
| (in thousands of U.S. dollars, except for per share data) | 2023 | 2022 | 2023 vs. 2022 | 2023 | 2022 | 2023 vs. 2022 | |||||||||||||||||||||||||
| Net revenue | $ | 193,771 | $ | 144,136 | $ | 49,635 | 34 | % | $ | 370,720 | $ | 297,347 | $ | 73,373 | 25 | % | |||||||||||||||
| Cost of goods sold | 146,362 | 101,254 | 45,108 | 45 | % | 279,115 | 205,851 | 73,264 | 36 | % | |||||||||||||||||||||
| Gross profit | 47,409 | 42,882 | 4,527 | 11 | % | 91,605 | 91,496 | 109 | 0 | % | |||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||||||||||
| General and administrative | 43,313 | 37,878 | 5,435 | 14 | % | 83,829 | 78,386 | 5,443 | 7 | % | |||||||||||||||||||||
| Selling | 7,583 | 9,669 | (2,086) | (22) | % | 14,442 | 19,340 | (4,898) | (25) | % | |||||||||||||||||||||
| Amortization | 21,917 | 23,995 | (2,078) | (9) | % | 44,142 | 48,354 | (4,212) | (9) | % | |||||||||||||||||||||
| Marketing and promotion | 9,208 | 8,535 | 673 | 8 | % | 17,743 | 15,783 | 1,960 | 12 | % | |||||||||||||||||||||
| Research and development | 56 | 165 | (109) | (66) | % | 135 | 331 | (196) | (59) | % | |||||||||||||||||||||
| Change in fair value of contingent consideration | 300 | — | 300 | 0 | % | (10,807) | 211 | (11,018) | (5,222) | % | |||||||||||||||||||||
| Litigation costs, net of recoveries | 3,042 | 2,815 | 227 | 8 | % | 5,076 | 3,260 | 1,816 | 56 | % | |||||||||||||||||||||
| Restructuring costs | 2,655 | 8,064 | (5,409) | (67) | % | 3,570 | 8,064 | (4,494) | (56) | % | |||||||||||||||||||||
| Transaction (income) costs | 1,094 | 3,552 | (2,458) | (69) | % | 9,596 | (9,264) | 18,860 | (204) | % | |||||||||||||||||||||
| Total operating expenses | 89,168 | 94,673 | (5,505) | (6) | % | 167,726 | 164,465 | 3,261 | 2 | % | |||||||||||||||||||||
| Operating loss | (41,759) | (51,791) | 10,032 | (19) | % | (76,121) | (72,969) | (3,152) | 4 | % | |||||||||||||||||||||
| Interest expense, net | (8,625) | (3,107) | (5,518) | 178 | % | (18,460) | (7,520) | (10,940) | 145 | % | |||||||||||||||||||||
| Non-operating income (expense), net | 821 | (18,450) | 19,271 | (104) | % | (3,581) | (51,442) | 47,861 | (93) | % | |||||||||||||||||||||
| Loss before income taxes | (49,563) | (73,348) | 23,785 | (32) | % | (98,162) | (131,931) | 33,769 | (26) | % | |||||||||||||||||||||
| Income tax (recovery) expense | (3,380) | (11,713) | 8,333 | (71) | % | 3,884 | (4,502) | 8,386 | (186) | % | |||||||||||||||||||||
| Net loss | $ | (46,183) | $ | (61,635) | $ | 15,452 | (25) | % | (102,046) | (127,429) | 25,383 | (20) | % | ||||||||||||||||||
| Net loss per share - basic and diluted | (0.07) | (0.11) | 0.04 | (41) | % | (0.17) | (0.24) | 0.07 | (30) | % | |||||||||||||||||||||
Condensed Consolidated Statements of Cash Flows
| For the six months | |||||||||||||||
| ended November 30, | Change | % Change | |||||||||||||
| (in thousands of US dollars) | 2023 | 2022 | 2023 vs. 2022 | ||||||||||||
| Cash used in operating activities: | |||||||||||||||
| Net loss | $ | (102,046) | $ | (127,429) | $ | 25,383 | (20) | % | |||||||
| Adjustments for: | |||||||||||||||
| Deferred income tax recovery | (4,042) | (12,941) | 8,899 | (69) | % | ||||||||||
| Unrealized foreign exchange (gain) loss | (5,604) | 2,261 | (7,865) | (348) | % | ||||||||||
| Amortization | 62,341 | 67,387 | (5,046) | (7) | % | ||||||||||
| (Gain) loss on sale of capital assets | (20) | 13 | (33) | (254) | % | ||||||||||
| Other non-cash items | (2,623) | 10,372 | (12,995) | (125) | % | ||||||||||
| Stock-based compensation | 16,458 | 20,136 | (3,678) | (18) | % | ||||||||||
| (Gain) loss on long-term investments & equity investments | (412) | 1,918 | (2,330) | (121) | % | ||||||||||
| Loss on derivative instruments | 7,992 | 18,997 | (11,005) | (58) | % | ||||||||||
| Change in fair value of contingent consideration | (10,807) | 211 | (11,018) | (5,222) | % | ||||||||||
| Change in non-cash working capital: | |||||||||||||||
| Accounts receivable | 4,524 | 6,690 | (2,166) | (32) | % | ||||||||||
| Prepaids and other current assets | 3,764 | (7,780) | 11,544 | (148) | % | ||||||||||
| Inventory | 8,669 | 5,046 | 3,623 | 72 | % | ||||||||||
| Accounts payable and accrued liabilities | (24,445) | (1,941) | (22,504) | 1,159 | % | ||||||||||
| Net cash used in operating activities | (46,251) | (17,060) | (29,191) | 171 | % | ||||||||||
| Cash provided by (used in) investing activities: | |||||||||||||||
| Investment in capital and intangible assets, net | (10,011) | (7,537) | (2,474) | 33 | % | ||||||||||
| Proceeds from disposal of capital and intangible assets | 365 | 2,160 | (1,795) | (83) | % | ||||||||||
| Disposal (purchase) of marketable securities, net | 125,479 | (243,186) | 368,665 | (152) | % | ||||||||||
| Business acquisitions, net of cash acquired | (60,626) | (24,372) | (36,254) | 149 | % | ||||||||||
| Net cash provided by (used in) investing activities | 55,207 | (272,935) | 328,142 | (120) | % | ||||||||||
| Cash provided by (used in) financing activities: | |||||||||||||||
| Share capital issued, net of cash issuance costs | — | 129,593 | (129,593) | (100) | % | ||||||||||
| Shares effectively repurchased for employee withholding tax | — | (1,189) | 1,189 | (100) | % | ||||||||||
| Proceeds from long-term debt | 32,621 | 1,288 | 31,333 | 2,433 | % | ||||||||||
| Repayment of long-term debt | (14,901) | (10,420) | (4,481) | 43 | % | ||||||||||
| Proceeds from convertible debt | 21,553 | — | 21,553 | 0 | % | ||||||||||
| Repayment of convertible debt | (107,330) | (48,975) | (58,355) | 119 | % | ||||||||||
| Repayment of lease liabilities | (91) | (1,114) | 1,023 | (92) | % | ||||||||||
| Net decrease in bank indebtedness | (3,200) | (2,819) | (381) | 14 | % | ||||||||||
| Net cash provided by (used in) financing activities | (71,348) | 66,364 | (137,712) | (208) | % | ||||||||||
| Effect of foreign exchange on cash and cash equivalents | 709 | (2,060) | 2,769 | (134) | % | ||||||||||
| Net decrease in cash and cash equivalents | (61,683) | (225,691) | 164,008 | (73) | % | ||||||||||
| Cash and cash equivalents, beginning of period | 206,632 | 415,909 | (209,277) | (50) | % | ||||||||||
| Cash and cash equivalents, end of period | $ | 144,949 | $ | 190,218 | $ | (45,269) | (24) | % | |||||||
Net Revenue by Operating Segment
| For the three months | For the three months | For the six months | For the six months | ||||||||||||||||||||||||||||
| (In thousands of U.S. dollars) | November 30, 2023 | % of Total Revenue | November 30, 2022 | % of Total Revenue | November 30, 2023 | % of Total Revenue | November 30, 2022 | % of Total Revenue | |||||||||||||||||||||||
| Cannabis business | $ | 67,114 | 34 | % | $ | 49,898 | 34 | % | $ | 137,447 | 37 | % | $ | 108,468 | 36 | % | |||||||||||||||
| Distribution business | 67,223 | 35 | % | 60,188 | 42 | % | 136,380 | 37 | % | 120,773 | 41 | % | |||||||||||||||||||
| Beverage alcohol business | 46,505 | 24 | % | 21,395 | 15 | % | 70,667 | 19 | % | 42,049 | 14 | % | |||||||||||||||||||
| Wellness business | 12,929 | 7 | % | 12,655 | 9 | % | 26,226 | 7 | % | 26,057 | 9 | % | |||||||||||||||||||
| Total net revenue | $ | 193,771 | 100 | % | $ | 144,136 | 100 | % | $ | 370,720 | 100 | % | $ | 297,347 | 100 | % | |||||||||||||||
Net Revenue by Operating Segment in Constant Currency
| For the three months | For the three months | For the six months | For the six months | ||||||||||||||||||||||||||||
| November 30, 2023 | November 30, 2022 | November 30, 2023 | November 30, 2022 | ||||||||||||||||||||||||||||
| (In thousands of U.S. dollars) | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | |||||||||||||||||||||||
| Cannabis business | $ | 67,361 | 35 | % | $ | 49,898 | 34 | % | $ | 138,750 | 38 | % | $ | 108,468 | 36 | % | |||||||||||||||
| Distribution business | 64,502 | 34 | % | 60,188 | 42 | % | 131,454 | 36 | % | 120,773 | 41 | % | |||||||||||||||||||
| Beverage alcohol business | 46,505 | 24 | % | 21,395 | 15 | % | 70,667 | 19 | % | 42,049 | 14 | % | |||||||||||||||||||
| Wellness business | 13,004 | 7 | % | 12,655 | 9 | % | 26,463 | 7 | % | 26,057 | 9 | % | |||||||||||||||||||
| Total net revenue | $ | 191,372 | 100 | % | $ | 144,136 | 100 | % | $ | 367,334 | 100 | % | $ | 297,347 | 100 | % | |||||||||||||||
Net Cannabis Revenue by Market Channel
| For the three months | For the three months | For the six months | For the six months | ||||||||||||||||||||||||||||
| (In thousands of U.S. dollars) | November 30, 2023 | % of Total Revenue | November 30, 2022 | % of Total Revenue | November 30, 2023 | % of Total Revenue | November 30, 2022 | % of Total Revenue | |||||||||||||||||||||||
| Revenue from Canadian medical cannabis | $ | 6,288 | 9 | % | $ | 6,365 | 13 | % | $ | 12,430 | 9 | % | $ | 12,885 | 12 | % | |||||||||||||||
| Revenue from Canadian adult-use cannabis | 72,048 | 107 | % | 52,390 | 106 | % | 143,243 | 104 | % | 110,745 | 101 | % | |||||||||||||||||||
| Revenue from wholesale cannabis | 4,289 | 7 | % | 236 | 0 | % | 9,584 | 7 | % | 628 | 1 | % | |||||||||||||||||||
| Revenue from international cannabis | 11,931 | 18 | % | 7,705 | 15 | % | 26,183 | 19 | % | 18,127 | 17 | % | |||||||||||||||||||
| Less excise taxes | (27,442) | (41) | % | (16,798) | (34) | % | (53,993) | (39) | % | (33,917) | (31) | % | |||||||||||||||||||
| Total | $ | 67,114 | 100 | % | $ | 49,898 | 100 | % | $ | 137,447 | 100 | % | $ | 108,468 | 100 | % | |||||||||||||||
Net Cannabis Revenue by Market Channel in Constant Currency
| For the three months | For the three months | For the six months | For the six months | ||||||||||||||||||||||||||||
| November 30, 2023 | November 30, 2022 | November 30, 2023 | November 30, 2022 | ||||||||||||||||||||||||||||
| (In thousands of U.S. dollars) | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | |||||||||||||||||||||||
| Revenue from Canadian medical cannabis | $ | 6,377 | 9 | % | $ | 6,365 | 13 | % | $ | 12,687 | 9 | % | $ | 12,885 | 12 | % | |||||||||||||||
| Revenue from Canadian adult-use cannabis | 73,021 | 108 | % | 52,390 | 106 | % | 146,132 | 106 | % | 110,745 | 101 | % | |||||||||||||||||||
| Revenue from wholesale cannabis | 4,338 | 7 | % | 236 | 0 | % | 9,796 | 7 | % | 628 | 1 | % | |||||||||||||||||||
| Revenue from international cannabis | 11,442 | 17 | % | 7,705 | 15 | % | 25,219 | 18 | % | 18,127 | 17 | % | |||||||||||||||||||
| Less excise taxes | (27,817) | (41) | % | (16,798) | (34) | % | (55,084) | (40) | % | (33,917) | (31) | % | |||||||||||||||||||
| Total | $ | 67,361 | 100 | % | $ | 49,898 | 100 | % | $ | 138,750 | 100 | % | $ | 108,468 | 100 | % | |||||||||||||||
Other Financial Information: Key Operating Metrics
| For the three months | For the six months | ||||||||||||||
| ended November 30, | ended November 30, | ||||||||||||||
| (in thousands of U.S. dollars) | 2023 | 2022 | 2023 | 2022 | |||||||||||
| Net cannabis revenue | $ | 67,114 | $ | 49,898 | $ | 137,447 | $ | 108,468 | |||||||
| Distribution revenue | 67,223 | 60,188 | 136,380 | 120,773 | |||||||||||
| Net beverage alcohol revenue | 46,505 | 21,395 | 70,667 | 42,049 | |||||||||||
| Wellness revenue | 12,929 | 12,655 | 26,226 | 26,057 | |||||||||||
| Cannabis costs | 46,472 | 28,577 | 96,989 | 57,438 | |||||||||||
| Beverage alcohol costs | 30,513 | 11,420 | 41,779 | 22,269 | |||||||||||
| Distribution costs | 60,147 | 52,495 | 121,615 | 107,479 | |||||||||||
| Wellness costs | 9,230 | 8,762 | 18,732 | 18,665 | |||||||||||
| Adjusted gross profit (excluding PPA step-up) (1) | 52,110 | 43,989 | 101,412 | 93,710 | |||||||||||
| Cannabis adjusted gross margin (excluding PPA step-up) (1) | 35 | % | 43 | % | 35 | % | 47 | % | |||||||
| Beverage alcohol adjusted gross margin (excluding PPA step-up) (1) | 38 | % | 52 | % | 44 | % | 52 | % | |||||||
| Distribution gross margin | 11 | % | 13 | % | 11 | % | 11 | % | |||||||
| Wellness gross margin | 29 | % | 31 | % | 29 | % | 28 | % | |||||||
| Adjusted EBITDA (1) | $ | 10,086 | $ | 11,008 | $ | 20,820 | $ | 23,839 | |||||||
| Cash and marketable securities (1) as at the period ended: | 259,791 | 433,504 | 259,791 | 433,504 | |||||||||||
| Working capital as at the period ended: | $ | 247,041 | $ | 388,200 | $ | 247,041 | $ | 388,200 | |||||||
Other Financial Information: Gross Margin and Adjusted Gross Margin
| For the three months ended November 30, 2023 | |||||||||||||||||||
| (In thousands of U.S. dollars) | Cannabis | Beverage | Distribution | Wellness | Total | ||||||||||||||
| Net revenue | $ | 67,114 | $ | 46,505 | $ | 67,223 | $ | 12,929 | $ | 193,771 | |||||||||
| Cost of goods sold | 46,472 | 30,513 | 60,147 | 9,230 | 146,362 | ||||||||||||||
| Gross profit | 20,642 | 15,992 | 7,076 | 3,699 | 47,409 | ||||||||||||||
| Gross margin | 31 | % | 34 | % | 11 | % | 29 | % | 24 | % | |||||||||
| Adjustments: | |||||||||||||||||||
| Purchase price accounting step-up | 2,938 | 1,763 | — | — | 4,701 | ||||||||||||||
| Adjusted gross profit | 23,580 | 17,755 | 7,076 | 3,699 | 52,110 | ||||||||||||||
| Adjusted gross margin | 35 | % | 38 | % | 11 | % | 29 | % | 27 | % | |||||||||
| For the three months ended November 30, 2022 | |||||||||||||||||||
| (In thousands of U.S. dollars) | Cannabis | Beverage | Distribution | Wellness | Total | ||||||||||||||
| Net revenue | $ | 49,898 | $ | 21,395 | $ | 60,188 | $ | 12,655 | $ | 144,136 | |||||||||
| Cost of goods sold | 28,577 | 11,420 | 52,495 | 8,762 | 101,254 | ||||||||||||||
| Gross profit | 21,321 | 9,975 | 7,693 | 3,893 | 42,882 | ||||||||||||||
| Gross margin | 43 | % | 47 | % | 13 | % | 31 | % | 30 | % | |||||||||
| Adjustments: | |||||||||||||||||||
| Purchase price accounting step-up | — | 1,107 | — | — | 1,107 | ||||||||||||||
| Adjusted gross profit | 21,321 | 11,082 | 7,693 | 3,893 | 43,989 | ||||||||||||||
| Adjusted gross margin | 43 | % | 52 | % | 13 | % | 31 | % | 31 | % | |||||||||
| For the six months ended November 30, 2023 | |||||||||||||||||||
| (In thousands of U.S. dollars) | Cannabis | Beverage | Distribution | Wellness | Total | ||||||||||||||
| Net revenue | $ | 137,447 | $ | 70,667 | $ | 136,380 | $ | 26,226 | $ | 370,720 | |||||||||
| Cost of goods sold | 96,989 | 41,779 | 121,615 | 18,732 | 279,115 | ||||||||||||||
| Gross profit | 40,458 | 28,888 | 14,765 | 7,494 | 91,605 | ||||||||||||||
| Gross margin | 29 | % | 41 | % | 11 | % | 29 | % | 25 | % | |||||||||
| Adjustments: | |||||||||||||||||||
| Purchase price accounting step-up | 7,454 | 2,353 | — | — | 9,807 | ||||||||||||||
| Adjusted gross profit | 47,912 | 31,241 | 14,765 | 7,494 | 101,412 | ||||||||||||||
| Adjusted gross margin | 35 | % | 44 | % | 11 | % | 29 | % | 27 | % | |||||||||
| For the six months ended November 30, 2022 | |||||||||||||||||||
| (In thousands of U.S. dollars) | Cannabis | Beverage | Distribution | Wellness | Total | ||||||||||||||
| Net revenue | $ | 108,468 | $ | 42,049 | $ | 120,773 | $ | 26,057 | $ | 297,347 | |||||||||
| Cost of goods sold | 57,438 | 22,269 | 107,479 | 18,665 | 205,851 | ||||||||||||||
| Gross profit | 51,030 | 19,780 | 13,294 | 7,392 | 91,496 | ||||||||||||||
| Gross margin | 47 | % | 47 | % | 11 | % | 28 | % | 31 | % | |||||||||
| Adjustments: | |||||||||||||||||||
| Purchase price accounting step-up | — | 2,214 | — | — | 2,214 | ||||||||||||||
| Adjusted gross profit | 51,030 | 21,994 | 13,294 | 7,392 | 93,710 | ||||||||||||||
| Adjusted gross margin | 47 | % | 52 | % | 11 | % | 28 | % | 32 | % | |||||||||
Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization
| For the three months | For the six months | ||||||||||||||||||||||||||||||
| ended November 30, | Change | % Change | ended November 30, | Change | % Change | ||||||||||||||||||||||||||
| (In thousands of U.S. dollars) | 2023 | 2022 | 2023 vs. 2022 | 2023 | 2022 | 2023 vs. 2022 | |||||||||||||||||||||||||
| Net loss | $ | (46,183) | $ | (61,635) | $ | 15,452 | (25) | % | $ | (102,046) | $ | (127,429) | $ | 25,383 | (20) | % | |||||||||||||||
| Income tax expense | (3,380) | (11,713) | 8,333 | (71) | % | 3,884 | (4,502) | 8,386 | (186) | % | |||||||||||||||||||||
| Interest expense, net | 8,625 | 3,107 | 5,518 | 178 | % | 18,460 | 7,520 | 10,940 | 145 | % | |||||||||||||||||||||
| Non-operating income (expense), net | (821) | 18,450 | (19,271) | (104) | % | 3,581 | 51,442 | (47,861) | (93) | % | |||||||||||||||||||||
| Amortization | 31,552 | 33,318 | (1,766) | (5) | % | 62,341 | 67,387 | (5,046) | (7) | % | |||||||||||||||||||||
| Stock-based compensation | 8,201 | 10,943 | (2,742) | (25) | % | 16,458 | 20,136 | (3,678) | (18) | % | |||||||||||||||||||||
| Change in fair value of contingent consideration | 300 | — | 300 | 0 | % | (10,807) | 211 | (11,018) | (5,222) | % | |||||||||||||||||||||
| Purchase price accounting step-up | 4,701 | 1,107 | 3,594 | 325 | % | 9,807 | 2,214 | 7,593 | 343 | % | |||||||||||||||||||||
| Facility start-up and closure costs | 300 | 3,000 | (2,700) | (90) | % | 900 | 4,800 | (3,900) | (81) | % | |||||||||||||||||||||
| Litigation costs, net of recoveries | 3,042 | 2,815 | 227 | 8 | % | 5,076 | 3,260 | 1,816 | 56 | % | |||||||||||||||||||||
| Restructuring costs | 2,655 | 8,064 | (5,409) | (67) | % | 3,570 | 8,064 | (4,494) | (56) | % | |||||||||||||||||||||
| Transaction (income) costs | 1,094 | 3,552 | (2,458) | (69) | % | 9,596 | (9,264) | 18,860 | (204) | % | |||||||||||||||||||||
| Adjusted EBITDA | $ | 10,086 | $ | 11,008 | $ | (922) | (8) | % | $ | 20,820 | $ | 23,839 | $ | (3,019) | (13) | % | |||||||||||||||
Other Financial Information: Adjusted net income (loss) per share
| For the three months | For the six months | ||||||||||||||||||||||||||||||
| ended November 30, | Change | % Change | ended November 30, | Change | % Change | ||||||||||||||||||||||||||
| 2023 | 2022 | Change | 2023 | 2022 | Change | ||||||||||||||||||||||||||
| Net loss attributable to stockholders of Tilray Brands, Inc. | $ | (49,008) | $ | (69,463) | $ | 20,455 | (29) | % | $ | (120,533) | $ | (142,945) | $ | 22,412 | $ | (0) | |||||||||||||||
| Non-operating income (expense), net | (821) | 18,450 | (19,271) | (104) | % | 3,581 | 51,442 | (47,861) | (93) | % | |||||||||||||||||||||
| Amortization | 31,552 | 33,318 | (1,766) | (5) | % | 62,341 | 67,387 | (5,046) | (7) | % | |||||||||||||||||||||
| Stock-based compensation | 8,201 | 10,943 | (2,742) | (25) | % | 16,458 | 20,136 | (3,678) | (18) | % | |||||||||||||||||||||
| Change in fair value of contingent consideration | 300 | — | 300 | 0 | % | (10,807) | 211 | (11,018) | (5,222) | % | |||||||||||||||||||||
| Facility start-up and closure costs | 300 | 3,000 | (2,700) | (90) | % | 900 | 4,800 | (3,900) | (81) | % | |||||||||||||||||||||
| Litigation costs, net of recoveries | 3,042 | 2,815 | 227 | 8) | % | 5,076 | 3,260 | 1,816 | 56 | % | |||||||||||||||||||||
| Restructuring costs | 2,655 | 8,064 | (5,409) | (67) | % | 3,570 | 8,064 | (4,494) | (56) | % | |||||||||||||||||||||
| Transaction (income) costs | 1,094 | 3,552 | (2,458) | (69) | % | 9,596 | (9,264) | 18,860 | (204) | % | |||||||||||||||||||||
| Adjusted net income (loss) | $ | (2,685) | $ | 10,679 | $ | (13,364) | (125) | % | $ | (29,818) | $ | 3,091 | $ | (32,909) | (1,065) | % | |||||||||||||||
| Adjusted net income (loss) per share - basic and diluted | $ | (0.00) | $ | 0.02 | $ | (0.02) | (121) | % | $ | (0.04) | $ | 0.01 | $ | (0.05) | (899) | % | |||||||||||||||
Other Financial Information: Free Cash Flow
| For the three months | For the six months | ||||||||||||||||||||||||||||||
| ended November 30, | Change | % Change | ended November 30, | Change | % Change | ||||||||||||||||||||||||||
| (In thousands of U.S. dollars) | 2023 | 2022 | 2023 vs. 2022 | 2023 | 2022 | 2023 vs. 2022 | |||||||||||||||||||||||||
| Net cash used in operating activities | $ | (30,409) | $ | 29,209 | $ | (59,618) | (204) | % | $ | (46,251) | $ | (17,060) | $ | (29,191) | 171 | % | |||||||||||||||
| Less: investments in capital and intangible assets, net | (5,836) | (3,840) | (1,996) | 52 | % | (9,646) | (5,377) | (4,269) | 79 | % | |||||||||||||||||||||
| Free cash flow | $ | (36,245) | $ | 25,369 | $ | (61,614) | (243) | % | $ | (55,897) | $ | (22,437) | $ | (33,460) | 149 | % | |||||||||||||||
| Add: growth CAPEX | 3,158 | — | 3,158 | 0 | % | 4,845 | — | 4,845 | NM | ||||||||||||||||||||||
| Add: cash income taxes related to Aphria Diamond | 8,502 | 3,893 | 4,609 | 118 | % | 14,216 | 9,380 | 4,836 | 52 | % | |||||||||||||||||||||
| Add: integration costs related to HEXO | 6,230 | — | 6,230 | 0 | % | 12,145 | — | 12,145 | NM | ||||||||||||||||||||||
| Adjusted free cash flow | $ | (18,355) | $ | 29,262 | $ | (47,617) | (163) | % | $ | (24,691) | $ | (13,057) | $ | (11,634) | (89 | )% | |||||||||||||||
1 Expected rankings based on Brewers Association 2022 Annual Report and expected sales volume.
FAQ
What is the net revenue reported by Tilray Brands, Inc. in Q2 of fiscal year 2024?
What was the percentage increase in Canadian cannabis net revenue for Tilray Brands, Inc.?
What was the percentage increase in international cannabis net revenue for Tilray Brands, Inc.?
What was the increase in beverage alcohol net revenue for Tilray Brands, Inc. in Q2 of fiscal year 2024?
What are Tilray Brands, Inc.'s financial savings related to the integration of HEXO acquisition?
